
Primex Pharmaceuticals:
The leading global
‘commercially focused’
innovative
Anaesthesia company
Portfolio Strategy 2021 - 2026
Launch OZALIN.
Expand geographically with established products: RECOFOL & OGNA.
Extend portfolio via new indications and acquisitions to strengthen ‘Triad’ of Anaesthesia.


Existing Primex Product Portfolio
Recofol (propofol):
- Recofol N – propofol with MCT/LCT formulation.
- Recofol EDTA – propofol plus EDTA.
- Propofo VET – propofol for animals.
OZALIN / OZASED* (2mg/ml oral midazolam solution):
- ADV6209 was the former name of the product.
- Licensed and approved for paediatric premedication and procedural sedation in the EU, UK and CH.
OGNA Dental Portfolio:
- Local Anaesthetic Portfolio – articaine, mepivicaine and lidocaine (spray & gel).
- Endodontic Medical Devices (CE marked).